- Home
- TRNO vs GDTC Comparison
TRNO vs GDTC Comparison
Compare TRNO & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNO
- GDTC
- Stock Information
- Founded
- TRNO 2009
- GDTC 2018
- Country
- TRNO United States
- GDTC Singapore
- Employees
- TRNO N/A
- GDTC N/A
- Industry
- TRNO Real Estate
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- TRNO Finance
- GDTC Health Care
- Exchange
- TRNO Nasdaq
- GDTC Nasdaq
- Market Cap
- TRNO N/A
- GDTC 23.7M
- IPO Year
- TRNO 2010
- GDTC 2023
- Fundamental
- Price
- TRNO $64.49
- GDTC $2.13
- Analyst Decision
- TRNO Hold
- GDTC Buy
- Analyst Count
- TRNO 8
- GDTC 1
- Target Price
- TRNO $69.38
- GDTC $5.00
- AVG Volume (30 Days)
- TRNO 854.2K
- GDTC 12.4K
- Earning Date
- TRNO 11-06-2024
- GDTC 01-01-0001
- Dividend Yield
- TRNO 3.04%
- GDTC N/A
- EPS Growth
- TRNO N/A
- GDTC N/A
- EPS
- TRNO 1.79
- GDTC N/A
- Revenue
- TRNO $348,681,000.00
- GDTC $330,254.00
- Revenue This Year
- TRNO N/A
- GDTC $4.46
- Revenue Next Year
- TRNO $14.44
- GDTC N/A
- P/E Ratio
- TRNO $35.99
- GDTC N/A
- Revenue Growth
- TRNO 15.84
- GDTC N/A
- 52 Week Low
- TRNO $50.42
- GDTC $1.20
- 52 Week High
- TRNO $71.63
- GDTC $5.50
- Technical
- Relative Strength Index (RSI)
- TRNO 44.09
- GDTC 69.51
- Support Level
- TRNO $61.80
- GDTC $1.96
- Resistance Level
- TRNO $67.12
- GDTC $2.16
- Average True Range (ATR)
- TRNO 1.44
- GDTC 0.15
- MACD
- TRNO 0.03
- GDTC 0.03
- Stochastic Oscillator
- TRNO 50.56
- GDTC 84.07
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.